Episode Synopsis "How was it for you? The experts discuss EASD 2019 (with John Wilding, Sanjay Kalra, and Lori Berard)"

Listen to our clinical advisors discussing their EASD 2019 highlights, including new treatment options for children and older adults with type 2 diabetes, the complexities surrounding hypoglycemia prevention, and the implications of the VERIFY trial. Find more on Medicine Matter diabetes More from EASD 2019

Listen "How was it for you? The experts discuss EASD 2019 (with John Wilding, Sanjay Kalra, and Lori Berard)"

More episodes of the podcast Medicine Matters diabetes

• Why psychosocial care matters: Supporting people with diabetes in the pandemic (with Michael Vallis)
• World Diabetes Day 2020: Why nurses make the difference (with Lori Berard and Sharon Tovey)
• EASD 2020: Highlights from the Editorial Board (with Sanjay Kalra, John Wilding and Lori Berard)
• Why psychosocial care matters: Disengagement with diabetes (with Bill Polonsky)
• Why psychosocial care matters: Optimal medication taking in diabetes (with Kirsty Winkley)
• Why psychosocial care matters: Working with people using diabetes technology (with Thomas Kubiak)
• Why psychosocial care matters: The psychological impact of hypoglycemia (with Christel Hendrieckx)
• Why psychosocial care matters: Diabetes distress (with William Polonsky)
• Why psychosocial care matters: The role of the PSAD (with Frank Snoek)
• The DiRECT approach to weight loss: Efficacious and pragmatic (with Alison Barnes)
• ADA 2020 Goes Virtual! Editorial Board conference highlights (with Lori Berard, John Wilding, & Sanjay Kalra
• Closed-loop insulin delivery research update from ADA 2020 (with Rayhan Lal)
• Is oral semaglutide a game changer or nice-to-have for type 2 diabetes? (with Neil Skolnik)
• Alison Evert on the ADA consensus report on nutrition therapy for adults with diabetes or prediabetes
• Peer mentoring for teens with type 1 diabetes (with Ashby Walker)
• How was it for you? The experts discuss EASD 2019 (with John Wilding, Sanjay Kalra, and Lori Berard)
• REWIND, DECLARE, and high-risk diabetes patients (with Kamlesh Khunti)
• Nephrologist expert commentary: The CREDENCE trial (with Andrew Frankel)
• Barriers to insulin: Management in type 2 diabetes patients (with Lori Berard)
• UK nutrition guidelines: A fresh approach (with John Wilding and Pamela Dyson)
• SGLT2 inhibitors: The story so far (with John Wilding)
• Dissecting the CANVAS trial (with Carol Wysham and Lori Berard)
• Primary care expert commentary: The CREDENCE trial (with Kevin Fernando)
• Researcher comment: The CREDENCE trial (with Vlado Perkovic)
• Barriers to insulin: Initiation in type 2 diabetes patients (with Lori Berard)